Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.


TSX:TH - Post by User

Comment by SPCEO1on Sep 07, 2023 5:21pm
196 Views
Post# 35625067

RE:RE:RE:RE:RE:Well?

RE:RE:RE:RE:RE:Well?Praying for the best for your Dad PWIB.

Given the proximity to their earnings release, insiders likely are blocked from trading. If there is a window open for them to trade, it will not be open for long if they are reporting results before the end of the month.

The big seller is clearly gone now, so that should help the stock recover. That incessent, indiscriminate selling led many to believe the stock was going belly-up even though the facts did not support that. 

They are also going to present at the HC Wainwright conference early next week so maybe we can get some color as to how they achieved what they did on the cash front so quickly in August.

I would also like to know if F8 is still scheduled for a Spetember filing (remember its approval its tied to the cash buffer remaining at $20 million post 3/31/24, if not approvved the cash buffer rises to $30 million (assuming the Marathon loan is not renegotiated before then).

I wonder if the low stock price attracted some interest in a takeover and that  threat helped spur the more frequent communications. Whatever the cause, it is something they hopefully will continue to do as we all know it will help the stock, and management itself, if they do.

PWIB123 wrote: No insider buying, which is so confusing.  These guys are either broke and/or do not understand the market or don't believe in their own abilities.  

https://www.canadianinsider.com/company-insider-filings?ticker=TH

I'm super happy to see our executive team finally begin issuing press releases with positive headlines to engage the market.  The share price is beginning to recover.  Only 500% more increase to breakeven now.  That's so much better than the 1000% I needed last week.  


<< Previous
Bullboard Posts
Next >>